Crohn's & Colitis UK
Guide
Oct 2023
For patients
Practical ways to lower the risks of medicines that suppress the immune system. You should not have live vaccines while on an immunosuppressant, but non-live vaccines such as the injected flu jab, COVID-19, Shingrix shingles and pneumococcal vaccines are safe. It explains checks for chickenpox immunity, the slightly raised risk of some cancers, especially skin cancer, and sun safety, plus food hygiene and travel precautions.
Topics
Immunosuppressants
Vaccinations and infections
Cancer risk and screening
Travel
Biologics and newer medicines
Jargon explained
immunosuppressant
live vaccine
non-live vaccine
Shingrix
pneumococcal vaccine
JAK inhibitor
anti-TNF
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Feb 2021
For professionals
European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.
Topics
Children and young people
Medicines
Diet and nutrition
Biologics and newer medicines
Jargon explained
paediatric
penetrating disease
stricturing disease
exclusive enteral nutrition
anti-TNF
immunomodulator
therapeutic drug monitoring
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Aug 2026
For professionals
The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.
Topics
Children and young people
Diet and nutrition
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
therapeutic drug monitoring
exclusive enteral nutrition
endoscopic remission
New England Journal of Medicine
Study
Jul 2024
Patients and professionals
A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.
Topics
Biologics and newer medicines
Research
Jargon explained
non-inferiority
endoscopic remission
anti-TNF
Cochrane
Systematic review
Aug 2019
Patients and professionals
Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.
Topics
Immunosuppressants
Surgery
Research
Jargon explained
postoperative recurrence
low certainty evidence
post-operative recurrence
thiopurine
5-ASA
anti-TNF
Cochrane
Systematic review
May 2020
Patients and professionals
Cochrane concluded that adalimumab works for keeping Crohn's in remission, including in people who had already tried another anti-TNF drug. Whether it helps after bowel surgery is still unclear.
Topics
Biologics and newer medicines
Jargon explained
anti-TNF
maintenance
quiescent
Crohn's & Colitis UK
Guide
Jan 2026
For patients
Explains why fistulas are more common in Crohn's, the different types (perianal is the most common), how they are found, including examination under anaesthetic and MRI, and treatment with medicines, setons and other surgery. It describes what living with a seton is like and gives clear urgent-help advice: contact your GP or 111 for fever, pain and pus, and 999 or A&E for possible sepsis.
Topics
Around the bottom (perianal)
Complications
Surgery
Urgent help
Biologics and newer medicines
Jargon explained
fistula
perianal fistula
seton
examination under anaesthetic
perianal abscess
sepsis
fistulotomy
anti-tnf
perianal
metronidazole
ciprofloxacin
Gut
Guideline
Sep 2014
For professionals
An international expert consensus on perianal fistulas in Crohn's. Key points: combine more than one test for an accurate picture, always drain infection before starting immune-suppressing treatment, anti-TNF medicines are the main treatment, and definitive surgical repair is only considered when the rectum is not inflamed.
Topics
Around the bottom (perianal)
Surgery
Biologics and newer medicines
Jargon explained
perianal fistula
anti-tnf
proctitis
seton
NICE
Guideline
May 2010
For professionals
NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.
Topics
Biologics and newer medicines
Medicines
Jargon explained
anti-TNF
biosimilar
conventional therapy
severe active Crohn's disease
NICE
Guideline
Aug 2015
For professionals
NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.
Topics
Biologics and newer medicines
Medicines
Jargon explained
anti-TNF
TNF-alpha inhibitor
patient access scheme
moderately to severely active
NICE
Guideline
Jul 2017
For professionals
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics
Biologics and newer medicines
Medicines
Jargon explained
interleukin inhibitor
TNF-alpha inhibitor
biological therapy
NICE
Guideline
Jun 2023
For professionals
NICE's appraisal recommending upadacitinib (Rinvoq), a tablet, for adults with moderate to severe Crohn's disease after a biologic has not worked, stopped working or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Medicines
Biologics and newer medicines
Jargon explained
JAK inhibitor
small molecule
TNF-alpha inhibitor